Literature DB >> 3434896

Molecular specificity of the antibody responses of cattle naturally and experimentally infected with cytopathic and noncytopathic bovine viral diarrhea virus biotypes.

R O Donis1, E J Dubovi.   

Abstract

The specificity of the humoral IgG response of cattle naturally or experimentally infected with bovine viral diarrhea virus (BVDV) was studied by radioimmunoprecipitation. Serum samples were tested against radiolabeled lysates of cells infected with cytopathic and noncytopathic biotypes of BVDV. A biotype-specific serologic marker was not detected. The specificity of the IgG induced in cows naturally or experimentally infected with either BVDV biotype was essentially the same. A strong IgG response to the 2 glycoproteins (56 to 58 kilodaltons, [kD] and 48 kD) of both biotypes and to the major polypeptides was induced in infected cells: 118 kD and 80 kD by cytopathic BVDV and only 118 kD by noncytopathic BVDV. The most consistent difference among cattle was the presence of IgG specific for the 37-kD polypeptide. Sequential serum sample collection after spontaneous and induced infections with either BVDV biotype did not indicate specific IgG markers for determining infection history. Sera from cattle with a confirmed diagnosis of mucosal disease and lacking neutralizing antibodies to BVDV usually lacked (greater than 80%) nonneutralizing BVDV-specific IgG. One animal had substantial amounts of IgG to the 80-kD polypeptide. Other cattle had less readily detectable amounts of IgG specific for 80-kD or 37-kD viral polypeptides.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3434896

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  14 in total

1.  Classical swine fever virus diagnostics and vaccine production in insect cells.

Authors:  M M Hulst; R J Moormann
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

2.  Severe thrombocytopenia in young calves experimentally infected with noncytopathic bovine viral diarrhea virus.

Authors:  W V Corapi; T W French; E J Dubovi
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

3.  The prevalence of bovine viral diarrhea virus infection in a population of feedlot calves in western Canada.

Authors:  L F Taylor; J Van Donkersgoed; E J Dubovi; R J Harland; J V van den Hurk; C S Ribble; E D Janzen
Journal:  Can J Vet Res       Date:  1995-04       Impact factor: 1.310

Review 4.  Bovine viral diarrhea virus: biotypes and disease.

Authors:  D Deregt; K G Loewen
Journal:  Can Vet J       Date:  1995-06       Impact factor: 1.008

5.  Pathogenesis of mucosal disease: a cytopathogenic pestivirus generated by an internal deletion.

Authors:  N Tautz; H J Thiel; E J Dubovi; G Meyers
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

6.  Complete genome sequence of a bovine viral diarrhea virus 2 from commercial fetal bovine serum.

Authors:  Hua Liu; Yan Li; Mingchun Gao; Kai Wen; Ying Jia; Xiaomei Liu; Wenlong Zhang; Bo Ma; Junwei Wang
Journal:  J Virol       Date:  2012-09       Impact factor: 5.103

7.  Fusion to C3d enhances the immunogenicity of the E2 glycoprotein of type 2 bovine viral diarrhea virus.

Authors:  Lingshu Wang; J Oriol Sunyer; Leonard J Bello
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

8.  Monoclonal antibody analyses of cytopathic and noncytopathic viruses from fatal bovine viral diarrhea virus infections.

Authors:  W V Corapi; R O Donis; E J Dubovi
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

9.  New concepts in the pathogenesis, diagnosis and control of diseases caused by the bovine viral diarrhea virus.

Authors:  O M Radostits; I R Littlejohns
Journal:  Can Vet J       Date:  1988-06       Impact factor: 1.008

10.  Pestivirus glycoprotein which induces neutralizing antibodies forms part of a disulfide-linked heterodimer.

Authors:  E Weiland; R Stark; B Haas; T Rümenapf; G Meyers; H J Thiel
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.